Evidence Growing Metformin Safe in Many With Diabetes and CKD Evidence Growing Metformin Safe in Many With Diabetes and CKD
Rates of acidosis comparable in metformin-treated and nontreated patients with type 2 diabetes and mild to moderate chronic kidney disease when eGFR is at least 30 mL/min/1.73 m2.Medscape Medical News
Conclusions: This study highlights that MMP-9 or CUBN-SNPs may exert effects on risk of susceptibility to DN or ESRD. We provide novel evidence on genetic susceptibility for macroangiopathy in patients with a missense variant of CUBN (Ile2984Val) in patients with T2D.Nephron
Authors: Zhang Y, Wang Y, Tao XJ, Li Q, Li FF, Lee KO, Li DM, Ma JH Abstract Purpose: To determine if the TSH is related to estimated glomerular filtration rate (eGFR) in T2D patients without overt thyroid dysfunction. Methods: A cohort study of 5936 T2D patients was assessed for thyroid and kidney functions, in whom 248 with subclinical hyperthyroidism and 362 with subclinical hypothyroidism. Serum creatinine and 24-hour urine albumin excretion (UAE) were collected. Chronic kidney disease (CKD) was defined as eGFR
Conclusions: This single-center study showed that the proportion and composition of NDRD differ among different age groups. Consistent with pathological features, some clinical indices such as hematuria and proteinuria showed different features among different age groups. PMID: 30539908 [PubMed - in process]
ConclusionsSimulation results suggest that canagliflozin 100 mg may provide better long-term health outcomes compared with glimepiride in Indian patients with T2DM inadequately controlled with metformin.
Abstract The Associazione Medici Diabetologi (AMD) annals initiative is an ongoing observational survey promoted by AMD. It is based on a public network of about 700 Italian diabetes clinics, run by specialists who provide diagnostic confirmation and prevention and treatment of diabetes and its complications. Over the last few years, analysis of the AMD annals dataset has contributed several important insights on the clinical features of type-2 diabetes kidney disease and their prognostic and therapeutic implications. First, non-albuminuric renal impairment is the predominant clinical phenotype. Even though associ...
Catheter ablation (CA) is much more effective in reducing symptoms and rhythm control compared to anti-arrhythmic drugs and recommended as a first-line treatment for patients with symptomatic atrial fibrillation (AF) . In spite of the ever-increasing evidences on benefits of CA, AF recurrence is common post CA and fewer AF patients are willing to accept ablation treatment in the clinical practice, which need to be taken consideration by the physicians before making the decision. Many clinical diseases or factors such as hypertension, type 2 diabetes mellitus, untreated obstructive sleep apnea, metabolic syndrome, chroni...
This article first summarizes the results reported with RAAS inhibitors, mainstay of nephroprotection in T2DM with albuminuria. Second, it describes the positive results with glucagon-like peptide-1 receptor agonists (GLP-1RAs) and, even more impressive, sodium-glucose cotransporter type 2 inhibitors (SGLT2is). Third, besides the potential of combined therapies, it briefly considers some new approaches currently in development. Expert opinion: RAAS inhibitors exert renoprotective effects beyond their blood pressure lowering effects while SGLT2is, and possibly GLP-1RAs, exert nephroprotection independently of their glucose-...
Is dapagliflozin an effective therapeutic option for patients with type 2 diabetes and chronic kidney disease? How does it impact clinical outcomes in these patients?Nephrology Dialysis Transplantation
ConclusionsModerate ‐increasing HbA1c trajectory is associated with renal disease progression in patients with T2DM, independent of mean HbA1c. The deleterious effects of deteriorating HbA1c trajectory highlight the importance of achieving sustained good glycemic control in diabetes management.This article is protected by copyright. All rights reserved.
ConclusionIn the setting of Italian family practice, sulfonylurea use is associated with progressive CKD in patients with T2DM. Metformin, at doses progressively reduced according to CKD stages, as recommended by guidelines, is not associated with fast progression.